42nd Remington Winter Course in Infectious Diseases
The annual Conference on Retroviruses and Opportunistic Infections (CROI)
7th Advances Against Aspergillosis
18th annual conference: Superbugs & Superdrugs
Find Practice Guidelines
The Infectious Diseases Society of America (IDSA) represents physicians, scientists and other health care professionals who specialize in infectious diseases. IDSA’s purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases.
IDSA & HIVMA Engage HHS on Drug Pricing and Innovation
IDSA and HIVMA wrote to HHS Secretary Burwell to distinguish efforts to incentivize development of desperately needed new drugs from recent actions to significantly increase the costs of decades old drugs.
IDSA Writes to Senate Aging Committee Ahead of Hearing on Drug Pricing Spikes
IDSA wrote to the Senate Special Committee on Aging ahead of a planned hearing on recent drug price spikes. The IDSA letter distinguished efforts to incentivize development of desperately needed new drugs from recent actions to significantly increase the costs of decades old drugs.
IDSA Leads Stakeholders In Support of R&D Tax Credit for Antibiotics and Rapid Diagnostics
Forty groups representing providers, patients, public health and industry joined a letter – circulated by IDSA – supporting the Reinvigorating Antibiotic and Diagnostic Innovation (READI) Act, H.R. 3539.
IDSA Statement: White House Antibiotic Stewardship Forum
At this week’s White House Forum on Stewardship, IDSA President Steve Calderwood, MD, FIDSA said, “Our expertise on diagnosing and treating patients with serious infectious diseases makes us particularly well suited to lead multi-disciplinary institution-level stewardship programs that will improve patient outcomes”
Senators Urged to Support Antibiotic R&D Bill
A bill to establish a new FDA approval pathway for antibacterial drugs to treat life-threatening infections where there exists an unmet medical need has been introduced in the Senate. IDSA members asked to engage their Senators.
IDSA Spearheads Advocacy Effort for AR Funding
IDSA was joined by 56 groups in a letter to congressional appropriators calling for funding to address antimicrobial resistance.
Better Tests, Better Care: The Promise of Next Generation Diagnostics
This report for policymakers highlights the need for new diagnostics and recommends policies to stimulate diagnostics R&D and clinical integration.
IDSA, PIDS, and HIVMA Comments on NIH Physician-Scientist Workforce Report
IDSA, along with PIDS and HIVMA, jointly commented on the NIH Physician-Scientist Workforce Working Group report highlighting recommendations to improve the state of the physician-scientist workforce.
1 of 8
Local Transmission of Zika Virus
Update: Interim Guidelines for Health Care Providers Caring for Pregnant Women and Women of Reproductive Age with Possible Zika Virus Exposure
New Lyme-disease-causing bacteria species discovered
CDC Press Release
Interim Guidelines for Prevention of Sexual Transmission of Zika Virus
FDA approves new drug for treatment of chronic hepatitis C genotypes 1 and 4
CDC issues Health Advisory on Flu Season
CDC Urging Dialysis Providers and Facilities to Assess and Improve Infection Control Practices to Stop Hepatitis C Virus Transmission in Patients Undergoing Hemodialysis
Recognizing, Managing, and Reporting Zika Virus Infections in Travelers Returning from Central America, South America, the Caribbean, and Mexico
>> Read More
From the PresidentZika VirusNext Editor of CIDNominate Your ColleagueJournal Club
Prompt use of antiviral medication may reduce length of stay in the hospital, especially in severe cases, a new CID study suggests.
The new guidelines underscore the importance of consulting an infectious diseases (ID) specialist to identify candidiasis quickly and ensure a good outcome.
Attracting the best and brightest to ID is a top priority for IDSA. The recent results of the 2016 ID Match, which were released on Dec. 2, 2015, reaffirm the importance of the Society’s ongoing efforts to promote the specialty.
IDSA, HIVMA and PIDS applaud the news that pharmacy benefit manager Express Scripts is taking steps to improve access to pyrimethamine for patients with toxoplasmosis. The three organizations urge others to also make this option available to their beneficiaries.
From the PresidentIDWeek 2015 RecapAddress Pyrimethamine AccessNew IDSA MOC ModulesJournal Club
Two new studies in CID suggest that statins may hinder the body’s immune response and flu vaccine effectiveness in seniors.
1 of 7
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2016 Infectious Diseases Society of America